Swiss researchers injected repair microrobots into injured spinal cords of fish and mice, offering new hope for regenerative medicine and future healing technologies.
Swiss researchers injected repair microrobots into injured spinal cords of fish and mice, offering new hope for regenerative medicine and future healing technologies.
New in our electronic collection:
➡️ Personalised #medicine. A Critical Approach to Data-Driven Medicine
🔗 https://doi.org/10.4324/9781003279556
#SocialSciences #BehavioralScience #health #data #OpenAccess #OpenScience #books #bookstodon
New in our electronic collection:
➡️ Personalised #medicine. A Critical Approach to Data-Driven Medicine
🔗 https://doi.org/10.4324/9781003279556
#SocialSciences #BehavioralScience #health #data #OpenAccess #OpenScience #books #bookstodon
NEW: After ProPublica contacted leading vaccine skeptic Dr. Joseph Mercola for an article on babies dying after parents turned down vitamin K shots, he publicly reversed his long-held stance that the shots weren't needed.
“The data is clear: vitamin K saves lives,” he wrote.
https://www.propublica.org/article/vitamin-k-shot-joseph-mercola-reversal-babies?utm_source=mastodon&utm_medium=social&utm_campaign=mastodon-post
#News #Health #PublicHealth #Children #Medicine #Vaccines #Parenting
NEW: Cancer drug Revlimid is one of the bestselling pharmaceutical products of all time, with total sales of over $100 billion. It also cost nearly $1,000 per pill, even though that same pill cost just 25 cents to make.
Listen to this episode of “Paper Trail” wherever you get your podcasts: https://www.propublica.org/podcast/revlimid-cancer-drugs-fda-healthcare?utm_source=mastodon&utm_medium=social&utm_campaign=mastodon-post
NEW: Cancer drug Revlimid is one of the bestselling pharmaceutical products of all time, with total sales of over $100 billion. It also cost nearly $1,000 per pill, even though that same pill cost just 25 cents to make.
Listen to this episode of “Paper Trail” wherever you get your podcasts: https://www.propublica.org/podcast/revlimid-cancer-drugs-fda-healthcare?utm_source=mastodon&utm_medium=social&utm_campaign=mastodon-post